Ligand Pharmaceuticals Inc (LGND) Earning Prediction
Ligand Pharmaceuticals Inc (LGND) is set to release its earnings performance on 02/26 07:00:00 ET in Pre-Market trading. Consensus forecasts predict a revenue of 58.16M and an earnings per share (EPS) of 0.63 for the . With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
Earnings Surprise Analysis
LGND Transcript
The earnings call indicates strong financial performance, with raised guidance and record high revenues. Product development shows momentum with potential blockbuster drugs and a robust pipeline. Market strategy is solid with royalty revenue growth and strategic investments. Financial health is stable with manageable expenses and significant cash reserves. Shareholder returns are likely supported by positive financial outcomes. Q&A insights reinforce optimistic guidance and strategic focus. Given the market cap, the stock price is expected to react positively, likely increasing by 2% to 8% over the next two weeks.
The earnings call summary highlights strong financial performance with significant revenue and EPS growth, positive product launches, and raised guidance. The Q&A session reveals management's focus on strategic investments and alignment with FDA initiatives, which are viewed positively by analysts. Despite competitive risks, the company's cash position and strategic investments provide a solid foundation. The raised guidance and strong product performance contribute to a positive outlook, suggesting a stock price increase of 2% to 8% over the next two weeks.
The earnings call highlights strong financial performance with improved GAAP and non-GAAP net income. Management's optimistic outlook on product launches and strategic partnerships, like with Merck, along with robust M&A opportunities, indicate strong growth potential. Although there are concerns about operating expenses and tax rates, the overall sentiment is positive, especially with expected revenue growth and strategic investments. The market cap suggests moderate reaction, leading to a positive stock price movement prediction.
Ligand's earnings report shows strong financial performance with a 46% increase in total revenue and robust royalty revenue growth. The strategic investment in Pelthos Therapeutics and expected 13% royalty on Zelsuvmi sales are positive catalysts. Despite a GAAP net loss, adjusted EPS and net income have improved. The Q&A reveals opportunities in special situations and geographic expansion for Qarziba, although there are concerns about drug pricing impacts. Overall, the positive financial metrics, strategic investments, and growth prospects outweigh the risks, suggesting a positive stock price movement.
LGND Report
Frequently Asked Questions
What is the Ligand Pharmaceuticals Inc {quarter} Earnings Release Date and Time?
Ligand Pharmaceuticals Inc (LGND) is scheduled to release its {quarter} earnings report on Feb 26, 2026, Pre-Market (approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
What Are the Consensus Forecasts for Ligand Pharmaceuticals Inc {quarter} Revenue and EPS?
Analysts' consensus predicts 58.16M in revenue and an EPS of 0.63 for Ligand Pharmaceuticals Inc's {quarter}.
What Does Intellectia's AI Predict for Ligand Pharmaceuticals Inc {quarter} Earnings?
Intellectia's exclusive AI algorithms forecast a {conclusion} for Ligand Pharmaceuticals Inc's {quarter} earnings, with a prediction date of Feb 26, 2026. Ligand Pharmaceuticals Inc {summary}
How Can I Use This Earnings Prediction to Trade LGND Stock?
Leverage Intellectia's AI forecast to position trades ahead of the Feb 26, 2026 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
How Accurate Is Intellectia's AI for Earnings Predictions Like Ligand Pharmaceuticals Inc {quarter}?
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
How does AI Earnings Prediction generate its forecasts?
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
When are the predictions available, and how often are they updated?
Predictions are generated two days before a company's earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They're updated in real-time if significant news breaks, ensuring you get fresh insights.
Can I use AI Earnings Prediction for all types of stocks?
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2025-2026 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
